Glacier Peak Capital’s Harvard Bioscience HBIO Stock Holding History

Glacier Peak Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-133,039	Closed	-$4.99M	–	57
2017 Q4	$4.99M	Sell	133,039 -420	-0.3%	-$14.2K	6.38%	7
2017 Q3	$5M	Buy	133,459 +1,760	+1%	+$52.1K	5.69%	10
2017 Q2	$3.36M	Buy	131,699 +11,741	+10%	+$290K	3.57%	11
2017 Q1	$3.12M	Buy	119,958 +4,325	+4%	+$125K	2.8%	12
2016 Q4	$3.53M	Buy	115,633 +50,321	+77%	+$1.28M	2.03%	12
2016 Q3	$1.78M	Buy	65,312 +20,641	+46%	+$573K	2.99%	7
2016 Q2	$1.28M	Hold	44,671	–	–	1.35%	17
2016 Q1	$1.35M	Sell	44,671 -555	-1%	-$15.7K	1.16%	20
2015 Q4	$1.57M	Buy	45,226 +2,752	+6%	+$94.1K	1%	27
2015 Q3	$1.61M	Buy	42,474 +1,688	+4%	+$78.5K	0.89%	29
2015 Q2	$2.33M	Buy	40,786 +18,103	+80%	+$1.03M	1.17%	26
2015 Q1	$1.32M	Buy	22,683 +7,791	+52%	+$419K	0.64%	42
2014 Q4	$844K	Buy	+14,892	New	+$710K	0.43%	47
2014 Q3	–	Sell	-20,331	Closed	-$925K	–	65
2014 Q2	$925K	Buy	+20,331	New	+$854K	0.58%	39

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Glacier Peak Capital's HBIO Position: Q1 2018 in Review

Glacier Peak Capital sold out of Harvard Bioscience (HBIO) in Q1 2018, closing a stake of 133,039 shares — an estimated $4.99M sold.

Glacier Peak Capital first reported a position in HBIO in Q2 2014 and held it in 14 quarters. The position peaked at $5M in Q3 2017. 71 funds tracked by Wall St. Rank hold HBIO as of Q1 2018.

Glacier Peak Capital reported no remaining Harvard Bioscience position as of Q1 2018 after selling out during the quarter.
Glacier Peak Capital sold 133,039 Harvard Bioscience shares in Q1 2018, an estimated $4.99M.
Glacier Peak Capital first reported a position in Harvard Bioscience in Q2 2014 and held it in 14 quarters.
Glacier Peak Capital's Harvard Bioscience position peaked at $5M in Q3 2017.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2018.

Based on Glacier Peak Capital's 13F filing for Q1 2018, filed 16 May 2018.